Healthy Subjects Clinical Trial
Official title:
The Reciprocal Interactions Between Red Raspberry Polyphenols and Gut Microbiome Composition Affect Insulin Sensitivity
The primary objective aims are to assess the effects of regular consumption of red raspberries (RRB) with and without fructooligosaccharide (FOS) on the composition of the gut microbiota after 4 week intake and in parallel characterize plasma and urine metabolite profiles examining qualitative and quantitative intervention associated changes.
The study will be performed as a single-blinded, randomized, crossover manner. Thirty
subjects (20 insulin resistant subjects and 10 healthy subjects) will be randomly assigned
into one of two sequences: sequence A (n=15) will be RRB then RRB+FOS (which means subject
will consume only RRB (125 g/day(d) (equivalent to 1 cup fresh RRB)) with breakfast for 4
weeks, and then after a 4-week washout period, that subject will consume the RRB with FOS
(125 g/d RRB and 8 g/d FOS) for 4 weeks); sequence B (n=15) will be RRB+FOS then RRB (which
means subject will receive the RRB with FOS for 4 weeks, a 4-week washout, and then the RRB
for another 4-week). At the beginning and end of each 4-week treatment, subjects will undergo
a 6-h Study Day (4 study days in 12-week study duration) followed by a 1-h next morning
follow-up visit.
Subjects will be required to meet several inclusion and exclusion criteria, which will be
assessed through online survey and on-site clinic assessments, including questionnaires,
blood analysis and anthropometric measures. Eligible subjects will be invited to participate
in the study. Each subject will be asked to come for 1 Screening Visit, 4 dinner pick-ups
(the day before each Study Day), 4 Study Days and 6 Weekly Meetings.
During the Screening Visit, subjects will read, sign and date a written Institutional Review
Board approved Informed Consent Form prior to performing any study procedure. And then they
will be assessed their qualification, instructed on the process for completing study
questionnaires and counseled to restrict intake of colored plant foods rich in phytonutrients
the 3 days prior to each Study Day. They will be asked to restrict alcohol intake,
coffee/tea/ caffeinated beverage intake and moderate / vigorous physical activity and to
drink plenty of water to maintain hydration in the 24 h prior to each Study Day. They will be
instructed to come to the Clinical Nutrition Research Center (CNRC) the day before each Study
Day to pick up their dinner meal and evening snack. Subjects will be asked to get at least 7
hours sleep and to come to the CNRC after a 10-h overnight fasting on each Study Day.
Each Study Day will require subjects to be in the clinic for ~7 h to complete all baseline
and post challenge beverage testing procedures, including a 6 h study day and a 1 h next
morning follow-up visit. Subjects will be evaluated for compliance with the protocol (diet,
exercise, sleep, fasting), have their body weight and blood pressure measured, ingest a cup
of red raspberry drink (250 g RRB (equivalent to 2 cups fresh RRB) and 64 g glucose) and
their blood, urine and feces samples will be collected.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |